MANCHESTER UNIVERSITY NHS FOUNDATION TRUST

Their core work

Manchester University NHS Foundation Trust is one of the largest NHS trusts in England, operating major teaching hospitals in Manchester. In H2020, they contribute clinical expertise, patient cohorts, and real-world healthcare data to European research consortia — particularly in rare diseases, drug safety monitoring in pregnancy, and digital health endpoints. Their role is typically as a third-party clinical site providing patient access, clinical validation, and specialist medical knowledge that academic-only consortia cannot deliver.

What they specialise in

How they've shifted over time

Early H2020 work (2015–2018) focused on elderly care, cognitive impairment, dementia screening, and regenerative medicine — including an ambitious tissue-engineered trachea project. From 2019 onward, the Trust shifted decisively toward rare diseases, pregnancy pharmacovigilance, and digital health endpoints, reflecting the NHS's growing role in large-scale European data-sharing initiatives. The move from device/therapy development toward data-driven clinical evidence and real-world monitoring marks a clear strategic pivot.

Moving strongly toward large-scale clinical data provision for rare diseases and drug safety monitoring, making them an increasingly valuable partner for consortia needing real-world patient evidence.

How they like to work

The Trust overwhelmingly participates as a third party (8 of 10 entries), meaning they are brought in by consortium members for specific clinical contributions rather than shaping project design. They work in very large consortia — 304 unique partners across 39 countries — but rarely lead or even hold direct participant status. This signals a reliable, low-overhead partner that delivers clinical access and data without demanding governance roles.

Exceptionally broad network of 304 unique partners across 39 countries, driven by participation in massive pan-European health programmes like EJP RD and ConcePTION. Their connections span virtually all EU member states plus associated countries, with particular density in Western European clinical research networks.

What sets them apart

As a major NHS teaching hospital trust, they offer something most academic partners cannot: direct access to diverse patient populations under a unified healthcare system with strong data governance. Their combination of clinical infrastructure, patient cohorts, and specialist medical staff makes them a go-to third party when European consortia need real-world clinical validation from the UK. Few organizations can simultaneously provide rare disease expertise, pregnancy cohorts, and imaging facilities at this scale.

Highlights from their portfolio

• TETRA
  Their largest directly-funded project (EUR 483,512) and most technically ambitious — developing autologous stem cell-seeded tissue-engineered trachea, a genuine regenerative medicine attempt.
• Solve-RD
  Major European effort to solve unsolved rare diseases using expert-driven and data-driven approaches across European Reference Networks — positions the Trust at the center of rare disease diagnostics.
• ConcePTION
  Building a pan-European ecosystem for pregnancy medication safety monitoring — a critical public health gap where NHS patient data is exceptionally valuable.